Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Study Progression on Non-small Cell Lung Cancer with EGFR Mutation  Treated by Immune Checkpoint Inhibitors].

Zhongguo fei ai za zhi = Chinese journal of lung cancer - 20 Aug 2018

Bai Rilan, Chen Naifei, Cui Jiuwei

Abstract excerpt

In recent years, epidermal growth factor receptor tyrosine kinase inhibitors have been recommended by many guidelines as first-line drugs for advanced non-small cell lung cancer (NSCLC) with EGFR gene mutations and no resistance. However, with the prolongation of medication time, most appear acquired resistance. In recent years, breakthroughs in inhibitors of programmed death-1 (PD-1) and its ligand (PD1 ligand,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to EGFR gene

Share to Immune System

Share to Lung Neoplasms

Share to Molecular Targeted Therapy

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 30172273
DOI: 10.3779/j.issn.1009-3419.2018.08.11
PMCID: PMC6105349

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Study Progression on Non-small Cell Lung Cancer with EGFR Mutation Treated by Immune Checkpoint Inhibitors].PMID 30172273Read ↗

[Progress of Immunotherapy in EGFR-mutated Advanced Non-small Cell Lung Cancer].Semantic proximity Read ↗

[Application of Immune Checkpoint Inhibitors in EGFR Mutant Advanced Non-small Cell Lung Cancer].Semantic proximity Read ↗

[Research Progress of Anti-PD-1/PD-L1 Therapy for Non-small Cell Lung Cancer with EGFR Mutation].Semantic proximity Read ↗

Immunotherapy in advanced non-small-cell lung cancer with EGFR mutations.Semantic proximity Read ↗

[Research Progress in Immune Checkpoint Inhibitors Combination Therapy Applied to Non-small Cell Lung Cancer after EGFR Mutation-targeted Therapy Resistance].Semantic proximity Read ↗

[Research Progress of Immunotherapy for Non-small Cell Lung Cancer with Drive Gene Mutation].Semantic proximity Read ↗

[Advances in ICIs Therapy after TKIs Resistance in Patients with EGFR Mutant NSCLC: A Review].Semantic proximity Read ↗

Research Progress in Immunotherapy of NSCLC With EGFR-Sensitive Mutations.Semantic proximity Read ↗

The progress and confusion of anti-PD1/PD-L1 immunotherapy for patients with advanced non-small cell lung cancer.Semantic proximity Read ↗

The efficacy and possible mechanisms of immune checkpoint inhibitors in treating non-small cell lung cancer patients with epidermal growth factor receptor mutation.Semantic proximity Read ↗

Update in Immunotherapy for Advanced Non-small Cell Lung Cancer: Treatment Sequencing and Best ChoicesSemantic proximity Read ↗

[Efficacy of Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer with Rare Mutation].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.